1. Home
  2. ALLO vs RRBI Comparison

ALLO vs RRBI Comparison

Compare ALLO & RRBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • RRBI
  • Stock Information
  • Founded
  • ALLO 2017
  • RRBI 1998
  • Country
  • ALLO United States
  • RRBI United States
  • Employees
  • ALLO N/A
  • RRBI N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • RRBI Hotels/Resorts
  • Sector
  • ALLO Health Care
  • RRBI Consumer Discretionary
  • Exchange
  • ALLO Nasdaq
  • RRBI Nasdaq
  • Market Cap
  • ALLO 371.8M
  • RRBI 377.0M
  • IPO Year
  • ALLO 2018
  • RRBI 2019
  • Fundamental
  • Price
  • ALLO $1.11
  • RRBI $55.78
  • Analyst Decision
  • ALLO Strong Buy
  • RRBI Buy
  • Analyst Count
  • ALLO 10
  • RRBI 1
  • Target Price
  • ALLO $8.90
  • RRBI $62.00
  • AVG Volume (30 Days)
  • ALLO 4.1M
  • RRBI 7.7K
  • Earning Date
  • ALLO 05-13-2025
  • RRBI 04-30-2025
  • Dividend Yield
  • ALLO N/A
  • RRBI 0.86%
  • EPS Growth
  • ALLO N/A
  • RRBI 13.23
  • EPS
  • ALLO N/A
  • RRBI 5.31
  • Revenue
  • ALLO N/A
  • RRBI $112,266,000.00
  • Revenue This Year
  • ALLO N/A
  • RRBI $4.69
  • Revenue Next Year
  • ALLO $9.07
  • RRBI $5.73
  • P/E Ratio
  • ALLO N/A
  • RRBI $10.55
  • Revenue Growth
  • ALLO N/A
  • RRBI 6.50
  • 52 Week Low
  • ALLO $0.86
  • RRBI $42.78
  • 52 Week High
  • ALLO $3.78
  • RRBI $62.13
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 38.30
  • RRBI 58.69
  • Support Level
  • ALLO $1.07
  • RRBI $54.50
  • Resistance Level
  • ALLO $1.15
  • RRBI $56.45
  • Average True Range (ATR)
  • ALLO 0.14
  • RRBI 1.24
  • MACD
  • ALLO -0.01
  • RRBI 0.05
  • Stochastic Oscillator
  • ALLO 27.17
  • RRBI 59.41

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About RRBI Red River Bancshares Inc.

Red River Bancshares Inc is the bank holding company for the red river bank. The principal business of the Bank is lending and accepting deposits from businesses, professionals, individuals, and public entities. The bank's primary deposit products are demand deposits, savings deposits, and time deposits. The bank maintains a diversified loan portfolio with a focus on commercial real estate (Owner Occupied and Non-Owner Occupied), one-to-four-family residential, commercial, and industrial loans, construction and development Loans, and others. also, provides Treasury Management Services, Private Banking Services, Brokerage Services, and Other Banking Services.

Share on Social Networks: